Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis

L. Okolicsanyi, M. Venuti, M. Strazzabosco, R. Orlando, G. Nassuato, R. M. Iemmolo, F. Lirussi, M. Muraca, A. M. Pastorino, G. Castelli

Research output: Contribution to journalArticlepeer-review

Abstract

The kinetics of p.o. (150 mg) and i.v. (50 mg) ranitidine was studied in nine healthy controls and in nine patients with compensated liver cirrhosis. Plasma concentrations and urinary recovery of unchanged drug were determined by high performance liquid chromatography. The pharmacokinetic data observed in the cirrhotic patients did not differ from those of controls after p.o or i.v. administration. Moreover, oral bioavailability was similar in controls and cirrhotics. In conclusion, the pharmacokinetics of ranitidine is not altered in patients with compensated liver cirrhosis.

Original languageEnglish
Pages (from-to)329-332
Number of pages4
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume22
Issue number6
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis'. Together they form a unique fingerprint.

Cite this